In this respect, recent studies showed that selective ablation of LGR5+ colorectal CSCs led to tumor regression, which was followed by tumor regrowth upon treatment cessation (de Sousa e Melo et al., 2017; Shimokawa et al., 2017). This evidence concerns the gene LGR5 and neoplasm.